Neuropace, Inc. NPCE Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $22.07M-2.0% | $26.59M+23.9% | $27.35M+29.9% | $23.52M+22.1% | $22.52M+24.3% | ||
| $4.02M-22.4% | $6.01M+13.9% | $6.19M+9.7% | $5.39M+5.2% | $5.18M+8.4% | ||
| $18.05M+4.1% | $20.58M+27.1% | $21.17M+37.3% | $18.13M+28.3% | $17.34M+30.0% | ||
| 81.8%+4.8pp | 77.4%+2.0pp | 77.4%+4.2pp | 77.1%+3.7pp | 77%+3.4pp | ||
| $7.19M-3.4% | $7.03M+16.1% | $6.58M+14.3% | $6.85M+12.9% | $7.44M+28.6% | ||
| $11.58M+5.3% | $10.94M+9.9% | $12.6M+26.9% | $12.04M+23.4% | $11M+9.7% | ||
| $4.84M+19.7% | $4.38M+14.1% | $4.59M+15.4% | $6.07M+33.6% | $4.05M-20.2% | ||
| $23.62M+5.0% | $22.35M+12.6% | $23.77M+20.9% | $24.96M+22.5% | $22.49M+7.7% | ||
| $23.62M+5.0% | $22.35M+12.6% | $23.77M+20.9% | $24.96M+22.5% | $22.49M+7.7% | ||
| -$5.57M-8.2% | -$1.77M+51.6% | -$2.6M+38.7% | -$6.82M-9.5% | -$5.15M+31.8% | ||
| -25.2%-2.4pp | -6.6%+10.4pp | -9.5%+10.6pp | -29%+3.3pp | -22.9%+18.8pp | ||
| $1.52M-29.4% | $1.6M-27.0% | $1.65M-24.6% | $2.06M-4.9% | $2.15M-4.7% | ||
| $565K-28.8% | $638K-6.3% | $667K-11.5% | $718K-5.8% | $793K-4.1% | ||
| -$165K-101% | $0— | $82K-62.6% | -$486K-505% | -$82K-261% | ||
| -$6.69M-1.5% | -$2.73M+48.0% | -$3.5M+35.9% | -$8.65M-15.1% | -$6.59M+26.2% | ||
| -30.3%-1.1pp | -10.3%+14.2pp | -12.8%+13.1pp | -36.8%+2.2pp | -29.3%+20.0pp | ||
| -$0.20+4.8% | -$0.08+52.9% | -$0.11+42.1% | -$0.260.0% | -$0.21+34.4% | ||
| -$0.20+4.8% | -$0.08+52.9% | -$0.11+42.1% | -$0.260.0% | -$0.21+34.4% | ||
| 33.7M+7.1% | 32.7M+12.3% | 33.1M+12.5% | 32.9M+13.9% | 31.5M+11.3% | ||
| 33.7M+7.1% | 32.7M+12.3% | 33.1M+12.5% | 32.9M+13.9% | 31.5M+11.3% | ||
| -$165K-101% | $0— | $82K-62.6% | -$486K-505% | -$82K-261% | ||
| $22.07M-2.0% | $26.59M+23.9% | $27.35M+29.9% | $23.52M+22.1% | $22.52M+24.3% | ||
| -$5.57M-8.2% | -$1.77M+51.6% | -$2.6M+38.7% | -$6.82M-9.5% | -$5.15M+31.8% | ||
| -$5.51M-8.0% | -$1.69M+53.2% | -$2.5M+39.7% | -$6.72M-9.7% | -$5.1M+32.0% | ||
| -$5.51M-8.0% | -$1.69M+53.2% | -$2.5M+39.7% | -$6.72M-9.7% | -$5.1M+32.0% | ||
| -25%-2.3pp | -6.3%+10.4pp | -9.1%+10.5pp | -28.6%+3.2pp | -22.6%+18.7pp | ||
| -$5.57M-8.2% | -$1.77M+51.6% | -$2.6M+38.7% | -$6.82M-9.5% | -$5.15M+31.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Neuropace, Inc.'s revenue?
- Neuropace, Inc. (NPCE) generated $99.5M in revenue over the trailing twelve months, up 18.1% year over year.
- Is Neuropace, Inc. profitable?
- Neuropace, Inc. is not currently profitable: it reported a net loss of $21.6M over the trailing twelve months, a -21.7% net margin.
- What are Neuropace, Inc.'s profit margins?
- Gross margin is 78.3% and operating margin is -16.8%, with a -21.7% net margin.
- What is Neuropace, Inc.'s earnings per share?
- Neuropace, Inc.'s diluted EPS over the trailing twelve months is $-0.65.
- Where does Neuropace, Inc.'s income statement data come from?
- Every line is extracted from Neuropace, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
